West Pharmaceutical Services, Inc. (WST) designs and manufactures containment and delivery systems for injectable medicines, including stoppers, seals, syringes, and self-injection devices. After rallying roughly 23% year to date and touching a 52-week high of $386 in July, the stock has become a focal point in discussions about whether it can reclaim the psychologically significant $400 mark — a level it last traded above in 2021.
The $400 target is not an arbitrary figure. It appears repeatedly across Wall Street research. Barclays upgraded the stock to Overweight with a $400 price target, while Citi has raised its objective to $412, and Evercore ISI has pushed its target as high as $425. Against a latest close near $338.65, that target implies meaningful but not unreasonable upside, making it a natural focus for investors evaluating the stock price target.
West's recent fundamentals have strengthened the bullish case. In the quarter ended June 30, 2026, the company reported net sales of $872.3 million, up 13.8% year over year, with organic net sales growth of 12.7%. Adjusted earnings per share (EPS) of $2.37 handily exceeded the consensus estimate of $2.08. Management also raised full-year 2026 EPS guidance to a range of $8.85 to $9.05, reflecting confidence in the business trajectory.
That momentum, however, has not translated into an unbroken climb. After the earnings release, shares sold off sharply — falling more than 7% in a single session in late July — and have since consolidated between roughly $330 and $360. The stock's valuation, at a price-to-earnings ratio in the mid-40s, means the market is already pricing in a meaningful growth premium.
The most compelling catalyst is West's product mix. The company has been shifting toward high-value products (HVP), including components for complex biologics and GLP-1-based medicines, which carry higher margins than its legacy standard products. This transition is boosting gross margin, which rose 2.0 percentage points year over year to 37.7% in the second quarter. Continued strength in GLP-1 and biologic volumes would support both revenue growth and profitability.
Analyst sentiment has also turned constructive. Barclays' upgrade to Overweight, Citi's $412 target, and coverage initiations from BNP Paribas Exane at $447 and Wolfe Research at $375 reflect a broad reassessment of the company's earnings power. With roughly 93.9% of shares institutionally held, sustained upgrades could reinforce buying pressure.
Valuation is the primary obstacle. At more than 40 times trailing earnings, the stock leaves little room for execution missteps. If GLP-1-related demand normalizes faster than expected, or if margin expansion stalls, the premium multiple could compress even if the underlying business remains solid.
The West Vantage segment adds another layer of uncertainty. The divestiture of the SmartDose on-body delivery system to AbbVie (ABBV) creates a revenue transition headwind, and management has flagged that the related contract exit could weigh on results before drug-handling activity recovers. Slower free-cash-flow conversion in recent quarters also bears watching, as it could limit capacity investments and shareholder returns.
The consensus analyst price target sits near $368, according to MarketBeat data aggregating roughly fifteen firms — modestly below the $400 objective but well above the current price. The range is wide: Jefferies holds a low target of $295, while BNP Paribas Exane's $447 target anchors the high end. The dispersion underscores genuine disagreement about how much of West's growth is already reflected in the share price.
From a technical analysis perspective, $386 — the 52-week high reached in July — is the most important resistance level between the current price and $400. A decisive breakout above that zone would open the path to the round-number target. On the downside, the stock has found buyers in the low-to-mid $330s in recent weeks, while the 200-day moving average near $291 provides a longer-term support reference. West's all-time high of roughly $475, set in September 2021, serves as a reminder that the $400 level has been reached before, though it remains well below current analyst forecasts.
Traders tracking West Pharmaceutical Services may also benefit from automated tools such as Tickeron's AI Daily Buy/Sell Signals. This product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Investors can use these signals to identify opportunities, monitor existing positions, and spot shifting market trends more efficiently. For those following West's progress toward $400, such tools can provide a structured, data-driven complement to fundamental and technical research.
A move to $400 for West Pharmaceutical Services is plausible but far from guaranteed. The strongest arguments in its favor are accelerating high-value product demand, margin expansion, and a wave of analyst upgrades that collectively target levels near or above $400. The most significant counterweights are a demanding valuation, the West Vantage transition, and the stock's failure so far to hold above its 52-week high.
Investors should monitor upcoming earnings results and guidance updates, the pace of GLP-1 and biologics-related demand, gross-margin trends, and whether shares can clear the $386 resistance zone. A sustained move through that level, backed by continued earnings beats, would meaningfully improve the odds that the $400 price forecast becomes reality.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, WST has been loosely correlated with STVN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if WST jumps, then STVN could also see price increases.
| Ticker / NAME | Correlation To WST | 1D Price Change % | ||
|---|---|---|---|---|
| WST | 100% | +0.03% | ||
| STVN - WST | 48% Loosely correlated | -0.92% | ||
| NVST - WST | 35% Loosely correlated | +0.73% | ||
| QDEL - WST | 33% Loosely correlated | -0.14% | ||
| RGEN - WST | 32% Poorly correlated | -1.93% | ||
| CAPN - WST | 32% Poorly correlated | +1.06% | ||
More | ||||
| Ticker / NAME | Correlation To WST | 1D Price Change % |
|---|---|---|
| WST | 100% | +0.03% |
| Pharmaceuticals: Other industry (51 stocks) | 39% Loosely correlated | -0.19% |
| Pharmaceuticals industry (156 stocks) | 11% Poorly correlated | -0.52% |